RVX History of Events

I decided to go back through some RVX history in order in order to refresh my brain on why I have stuck with this investment. The bolding is mine.

After reading through the events and incredible discoveries that apabetalone has achieved over the yeas the picture that formed in my mind was of a team of so called business experts (bumpkins) standing on top of a gold mine, with proven reserves, starring at each other not having a clue of how to get the gold out of the ground.

I’ve left the various financings (mostly private placements) out of this summary but the picture I get from that aspect (funding) is the continuous inability to sufficiently fund properly powered trials, hence the regular failure in spite of extremely promising science both from internal studies and the research conducted by independent academic scientists. I’ll summarize the financing picture if I get time.

This is very unfortunate for patients, investors, the field of epigenetics and, to some extent, the RVX team, although they are well compensated.

Payout of the debenture is only 3 months away.

I’m still long on my investment irrespective of the incompetence on the business side of RVX. I sure hope Don does not get to spend any time on ZCC issues.

Frustrated

Toinv

Sept 23, 2017 - RESVERLOGIX PROVIDES GROUNDBREAKING RESULTS IN PATIENTS WITH SEVERE KIDNEY IMPAIRMENTS

Feb 13, 2017 - RESVERLOGIX HIGHLIGHTS UNIQUE PROPERTIES OF APABETALONE IN BOTH A RARE MUSCULAR DYSTROPHY (FSHD) AND NEURODEGENERATIVE EYE DISEASE

May 15, 2017 - RESVERLOGIX RECEIVES APPROVAL FROM THE FDA CARDIOVASCULAR AND RENAL DIVISION TO PROCEED WITH A REQUESTED APABETALONE CLINICAL TRIAL

May 30, 2017 - RESVERLOGIX RECEIVES APPROVAL FROM HEALTH CANADA TO PROCEED WITH FABRY DISEASE CLINICAL TRIAL WITH LEAD COMPOUND APABETALONE

July 10, 2017 - RESVERLOGIX RANDOMIZES FIRST PATIENT IN TAIWAN/CHINA PORTION OF THE PHASE 3 BETONMACE CLINICAL TRIAL

July 25, 2017 - RESVERLOGIX RECEIVES APPROVAL PATHWAY FROM THE FDA AS TO THE INCLUSION OF USA PATIENTS IN THE PHASE 3 BETONMACE TRIAL

Aug 29, 2017 - SUCCESSFUL CANTOS INFLAMMATION TRIAL SUPPORTS RATIONALE FOR RESVERLOGIX' ONGOING BETONMACE TRIAL

Oct 13, 2017 - RESVERLOGIX ANNOUNCES $87 MILLION PRIVATE PLACEMENT WITH SHENZHEN HEPALINK

Oct 24, 2017 - RESVERLOGIX ANNOUNCES RIGHT OF FIRST REFUSAL AGREEMENT WITH HEPALINK USA INC

Dec 6, 2017 - RESVERLOGIX REPAYS $68.8 MILLION LOAN

Dec 12, 2017 - NATURE’S RECENT SCIENTIFIC REPORTS PUBLICATION DESCRIBES HOW APABETALONE MAY BE A POWERFUL AGENT AGAINST HIV-1

Mar 28 – 2018 - RESVERLOGIX ANNOUNCES TWO NEW PUBLICATIONS ON APABETALONE IN KIDNEY DISEASE

June 7, 2018 - RESVERLOGIX HIGHLIGHTS POTENTIAL TO DEVELOP APABETALONE AS A THERAPEUTIC FOR HIV-1 ERADICATION UTILIZING THE “SHOCK AND KILL” APPROACH

July 31, 2018 - RESVERLOGIX INTENDS TO PURSUE U.S. LISTING

Nov 28, 2018 - RESVERLOGIX ANNOUNCES PUBLICATION ON APABETALONE IN ATHEROSCLEROSIS JOURNAL

MAR 18, 2019 - RESVERLOGIX PROUDLY ANNOUNCES FUNDING FOR PHASE 2 TRIAL EVALUATING APABETALONE IN PULMONARY ARTERIAL HYPERTENSION LED BY QUEBEC HEART AND LUNG INSTITUTE – LAVAL UNIVERSITY RESEARCHER

May 6, 2019 - RESVERLOGIX ANNOUNCES PUBLICATION ON APABETALONE IN HIGH-IMPACT AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (AJRCCM)

July 15, 2019 - RESVERLOGIX ANNOUNCES PUBLICATION ON APABETALONE IN CLINICAL EPIGENETICS

Aug 14, 2019 - RESVERLOGIX TO PRESENT AT THE EUROPEAN SOCIETY OF CARDIOLOGY’S ESC CONGRESS 2019

Sept 30, 2019 - RESVERLOGIX ANNOUNCES TOPLINE RESULTS IN BETONMACE PHASE 3 EPIGENETICS TRIAL

Dec 20- 2019 - RESVERLOGIX APPOINTS DICKY TO (ORI) TO ITS BOARD OF DIRECTORS

Feb 2020 – first signs of Covid emerging globally

Feb 3, 2020 - RESVERLOGIX RECEIVES US FDA BREAKTHROUGH THERAPY DESIGNATION FOR APABETALONE

Mar 23, 2020 - RESVERLOGIX INVITES COLLABORATIONS FOR USE OF APABETALONE IN TRIALS AND STUDIES TO COMBAT THE SPREAD OF COVID-19 BASED ON NEW RESEARCH

Mar 24, 2020 - RESVERLOGIX CLINICAL CANDIDATE APABETALONE FEATURED AS A POTENTIAL COVID-19 TREATMENT IN RECENT PUBLICATION

June 1, 2020 - RESVERLOGIX PLANS COVID-19 CLINICAL TRIAL PROGRAM LAUNCH

June 22, 2020 - RESVERLOGIX REACHES AGREEMENT WITH FDA FOR KEY ASPECTS OF APABETALONE REGISTRATION ENABLING STUDY

Oct 26, 2020 - A SECOND PUBLICATION SHORTLISTS RESVERLOGIX CLINICAL CANDIDATE APABETALONE FOR ITS POTENTIAL COVID-19 EFFECTIVENESS INCLUDING REDUCING CYTOKINE STORMS

DEC 22, 2020 - RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2020 MEETING OF SHAREHOLDERS AND UPDATE ON $13 MILLION INVESTMENT BY SHEIKH ABDULGADER ABOUD BAESHEN

Dec 22, 2020 - RESVERLOGIX ANNOUNCES APABETALONE TREATMENT PRIOR TO SARS-COV-2 (COVID-19) EXPOSURE SIGNIFICANTLY REDUCES VIRAL INFECTION – CONFIRMS PLANS FOR COVID-19 CLINICAL TRIAL

Jan 12, 2021 - APABETALONE’S POSITIVE EFFECT ON HOSPITALIZED PATIENTS INVOLVING HEART FAILURE

Feb 4, 2021 – Corporate update which shows on page 7 a potential trial design for BoM2 allegedly discussed with BPs with a patient size of 10,000 and cost of $200,000,000 to be funded by BP with an end date in 2025. This was followed by an alternative trial design of 3,600 patients at a cost of $60 to $70 million with a potential completion in 2023.

Mar 3, 2021 - NEW PUBLISHED EVIDENCE OF APABETALONE’S BENEFICIAL EFFECTS ON COVID-19

Mar 15, 2021 - APABETALONE TREATMENT PREVENTS COVID-19 INFECTION OF HUMAN LUNG CELLS

Mar 17, 2021 - APABETALONE’S BENEFICIAL EFFECTS ON COVID-19 PUBLISHED IN PRESTIGIOUS SCIENTIFIC JOURNAL CELL

Apr 12, 2021 - HEALTH CANADA ISSUES RESVERLOGIX AUTHORIZATION TO BEGIN IMMEDIATE CLINICAL STUDIES OF APABETALONE FOR COVID-19

Apr 20, 2021 - APABETALONE’S POSITIVE IMPACT ON COVID-19 IN HUMAN LUNG CELLS PUBLISHED IN BIOMEDICINES

Apr 27, 2021 - RESVERLOGIX’S APABETALONE DEMONSTRATES A MEDICAL FIRST IN PATIENTS WITH CHRONIC KIDNEY DISEASE

June 3, 2021 - RESVERLOGIX AND EVERSANA ANNOUNCE PARTNERSHIP TO SUPPORT THE PENDING LAUNCH OF THE INITIAL COMMERCIALIZATION OF APABETALONE FOR COVID-19 IN THE UNITED STATES AND CANADA

Sept 8, 2021 - RESVERLOGIX ANNOUNCES APABETALONE MEETS PRIMARY ENDPOINT IN A PULMONARY ARTERIAL HYPERTENSION PILOT STUDY

Sept 13, 2021 - STUDY DEMONSTRATES RESVERLOGIX’S APABETALONE TREATMENT SIGNIFICANTLY IMPROVES COGNITION AND REDUCES COGNITIVE DECLINE AMONG PATIENTS WITH BOTH CARDIOVASCULAR DISEASE AND DIABETES MELLITUS

Nov 1, 2021 - RESVERLOGIX IN ACTIVE DISCUSSIONS WITH THE KINGDOM OF MOROCCO’S MINISTRY OF HEALTH FOR THE LAUNCH OF COVID-19 CLINICAL STUDIES WITH FIRST-IN-CLASS DRUG APABETALONE

Nov 3, 2021 - RESVERLOGIX ENTERS INTO A COOPERATION AGREEMENT WITH THE SUPREME COUNCIL OF THE ARAB-AFRICAN ECONOMY TO SUPPORT THE DEVELOPMENT OF APABETALONE FOR COVID-19 PATIENTS

Feb 17, 2022 - RESVERLOGIX EXPANDS PHASE 2B CLINICAL TRIAL FOR COVID-19 TREATMENT WITH FIRST SITE IN BRAZIL AND SECOND IN CANADA

Mar 17, 2022 - APABETALONE’S POSITIVE IMPACT ON PULMONARY ARTERIAL HYPERTENSION PUBLISHED IN THE AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Apr 19, 2022 – RESVERLOGIX ANNOUNCES THE EXTENTION OF IT’S DEBENTURE DEADLINE FOR 1 YEAR

May 9, 20022 - RESVERLOGIX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A PHASE 3 HIGH-RISK COVID-19 OUTPATIENT STUDY

June 8, 2022 - RESVERLOGIX ANNOUNCES NEW RESEARCH FINDINGS HIGHLIGHTING THE SAFETY OF BD2-SELECTIVE BET INHIBITORS

Aug 15, 2022 - RESVERLOGIX ANNOUNCES APPOINTMENT OF NEW CHIEF SCIENTIFIC OFFICER

Aug 22, 2022 - RESVERLOGIX PUBLISHES NEW DATA HIGHLIGHTING APABETALONE’S BENEFIT IN NON-ALCOHOLIC FATTY LIVER DISEASE